BioSpace News Archive

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, reported its financial results for the third quarter 2021.

Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial results for the third quarter ended September 30, 2021, after the market close on Tuesday, November 9, 2021.

Zynex, Inc.Zynex, Inc., an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, reported financial results for its third quarter ended September 30, 2021.

Halozyme Therapeutics, Inc.Halozyme Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2021 and provided an update on its recent corporate activities and outlook.

Cardiol Therapeutics Inc., a clinical-stage biotechnology company focused on developing anti-inflammatory therapies for the treatment of cardiovascular disease, has filed a preliminary prospectus supplement to its short form base shelf prospectus dated August 3, 2021 in connection with a proposed public offering of units.

Avidity Biosciences, Inc. a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the Avidity management team will be participating at the following conferences.

Exact Sciences Corp. announced that the company generated revenue of $456.4 million for the third quarter ended September 30, 2021, compared to $408.4 million for the same period of 2020.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), today announced that it will host a virtual Key Opinion Leader (KOL) event focused on Hepatitis Delta Virus (HDV) infection.

Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced that management will participate in the following upcoming investor conferences.

Vertex Pharmaceuticals Incorporated reported consolidated financial results for the third quarter ended September 30, 2021 and raised full-year 2021 product revenue guidance to $7.4 to $7.5 billion.